Algorithme Pharma, an Altasciences company, has completed the validation of its expanded bioanalytical offering, Ligand Binding Bioanalysis. The new service allows the company to further enhance the support of Phase I/first-in-human and late-phase clinical trials conducted locally or globally, providing key information for sponsors as they look to make critical decisions in a timely fashion. The Ligand Binding Bioanalysis team, headed by scientific executive Dr. Robert Massé, offers extensive ...